Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) posted its earnings results on Tuesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), Briefing.com reports. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. The company’s quarterly revenue was up .0% compared to the same quarter last year.
Shares of Aurinia Pharmaceuticals (AUPH) traded down $0.15 during mid-day trading on Tuesday, hitting $5.62. 729,100 shares of the stock traded hands, compared to its average volume of 3,840,873. Aurinia Pharmaceuticals has a one year low of $2.02 and a one year high of $10.54.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://transcriptdaily.com/2017/11/15/aurinia-pharmaceuticals-inc-auph-issues-earnings-results.html.
A number of research firms have recently issued reports on AUPH. Leerink Swann lifted their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. BidaskClub cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 24th. Vetr cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.72 price objective for the company. in a research report on Monday, August 14th. Finally, Cantor Fitzgerald set a $14.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $10.79.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.